03 May 21. Featured Paper

Link to paper on Circulation

 

Authors

Tania A. Pawade, Mhairi K. Doris, Rong Bing, Audrey C. White, Laura Forsyth, Emily Evans, Catriona Graham, Michelle C. Williams, Edwin J.R. van Beek, Alison Fletcher, Philip D. Adamson, Jack P.M Andrews, Timothy R. G. Cartlidge, William S.A. Jenkins, Maaz Syed, Takeshi Fujisawa, Christophe Lucatelli, William Fraser, Stuart H. Ralston, Nicholas Boon, Bernard Prendergast, David E. Newby, & Marc R. Dweck

 

Abstract

Background: Valvular calcification is central to the pathogenesis & progression of aortic stenosis, with pre-clinical & observational studies suggesting that bone turnover & osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms.

We aimed to establish whether inhibition of these pathways with denosumab or alendronic acid could reduce disease progression in aortic stenosis.

Methods: In a single-centre parallel group double-blind randomized controlled trial, patients over 50 years of age with calcific aortic stenosis (peak aortic jet velocity >2.5 m/s) were randomized 2:1:2:1 to denosumab (60 mg every 6 months), placebo injection, alendronic acid (70 mg once weekly) or placebo capsule.

Participants underwent serial assessments with Doppler echocardiography, computed tomography aortic valve calcium scoring & 18F-sodium fluoride positron emission tomography & computed tomography.

The primary endpoint was the calculated 24-month change in aortic valve calcium score.

Results: One-hundred & fifty patients (mean age 72±8 years; 21% female) with calcific aortic stenosis (peak aortic jet velocity 3.36 [2.93 to 3.82] m/s; aortic valve calcium score 1152 [655 to 2065] Agatston Units) were randomized & received the allocated trial intervention: denosumab (n=49), alendronic acid (n=51) & placebo (injection n=25, capsule n=25; pooled for analysis).

Serum C-terminal telopeptide, a measure of bone turnover, halved from baseline to 6 months with denosumab (0.23 [0.18 to 0.33] to 0.11 [0.08 to 0.17] µg/L) & alendronic acid (0.20 [0.14 to 0.28] to 0.09 [0.08 to 0.13] µg/L) but was unchanged with placebo (0.23 [0.17 to 0.30] to 0.26 [0.16 to 0.31] µg/L).

There were no differences in 24-month change in aortic valve calcium score between denosumab & placebo (343 [198 to 804] AU versus 354 [76 to 675] AU, p=0.41), or alendronic acid & placebo (326 [138 to 813] AU versus 354 [76 to 675] AU, p=0.49).

Similarly, there were no differences in change in peak aortic jet velocity or 18F-sodium fluoride aortic valve uptake.

Conclusions: Neither denosumab nor alendronic acid affected progression of aortic valve calcification in patients with calcific aortic stenosis.

Alternative pathways & mechanisms need to be explored to identify disease-modifying therapies for the growing population of patients with this potentially fatal condition.

 

Keywords

• Aortic stenosis
• Aortic valve calcium score
• Computed tomography